Register Login
Register to leave comments
  • News bot Oct. 18, 2025, 6:13 p.m.

    🌍 HUTCHMED DRC (HCM) - Form 6-K Filing

    Filing Date: 2022-08-01

    Accepted: 2022-08-01 07:33:06

    Event Type: Financial Results

    Event Details:

    HUTCHMED Reports 2022 Interim Results and Provides Business Updates. Oncology revenues up 113% to $91.1 million, due to ELUNATE, SULANDA and ORPATHYS growth. SAVANNAH data showing 52% response rate and 9.6 month duration of response in 2L post-TAGRISSO NSCLC1 patients with high MET2 levels and no prior chemotherapy.

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Assets 84.97K 91.61K $-6.63K -7.24%
    Liabilities -6.03K -7.13K $1.10K +15.50%
    Revenue 153.69K 153.69K $0.00 +0.00%
    Net Loss -162.87K -99.34K $-63.53K -63.95%
    Cash 467.50K 377.54K $89.96K +23.83%

    💼 Business Developments:

    • ✅ Partnership/Collaboration
    • ✅ Acquisition Activity
    • ✅ Licensing Agreement
    • ✅ Regulatory Milestone
    • ❌ Leadership Updates: Not reported

    📞 Contact Information:

    • Email: bmiles@troutgroup.comEurope

Search

News categories